The 1 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 6.00, with a high estimate of 6.00 and a low estimate of 6.00. The median estimate represents a +325.53% increase from the last price of 1.41.
The current consensus among 2 polled investment analysts is to Buy stock in Nabriva Therapeutics PLC. This rating has held steady since March, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.43
Reporting Date Aug 12
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.